文献速递甲状腺疾病

RASAL1异常剪接变体RASAL1-004作为甲状腺癌新致癌机制

Functional Loss of the Tumor Suppressor Gene RASAL1 Through Formation of Aberrant Splice Variant RASAL1-004 as a Novel Oncogenic Mechanism in Thyroid Cancer.
PubMed 文献 · Thyroid · 2025-12-22

本研究探索异常选择性剪接作为RASAL1在甲状腺癌中失活的新机制。通过生物信息学和分子实验,鉴定出RASAL1-004变体,其外显子18.1跳跃与患者不良生存显著相关,并通过核糖体停滞和蛋白构象改变导致RASAL1功能丧失,促进甲状腺癌发生。

要点

  • RASAL1-004是RASAL1的异常剪接变体,常见外显子18.1跳跃。
  • RASAL1-004高表达与甲状腺癌患者不良生存显著相关。
  • RASAL1-004通过核糖体停滞和PH结构域构象改变丧失RAS失活功能。

核心结论

  • RASAL1通过异常剪接形成RASAL1-004导致功能丧失,是甲状腺癌新的致癌机制。

研究设计与样本

  • 采用综合生物信息学和分子实验方法鉴定并表征RASAL1异常剪接变体。

主要发现

  • RASAL1中外显子18.1跳跃导致RASAL1-004转录本在癌症中大量形成。
  • RASAL1-004丰度与甲状腺癌患者不良生存显著相关。
  • Argonaute2结合外显子17含CCAGCC基序的响应元件调控外显子18.1剪接。
  • 外显子18.1跳跃引起RNA结构改变导致核糖体停滞,停止RASAL1翻译。
  • RASAL1-004缺失外显子18.1改变PH结构域构象,丧失细胞膜定位和RAS失活功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RASAL1 is a prominent tumor suppressor gene through inactivating RAS, whose functional loss has been widely found to play an important role in thyroid cancer and occurs usually through its genetic and epigenetic inactivation. In this study, we intended to explore aberrant alternative splicing (AS) as an important novel mechanism for the oncogenic inactivation of RASAL1 in thyroid cancer. METHODS: We used comprehensive bioinformatic and molecular experimental approaches to identify and characterize aberrant alternative splice variants of RASAL1. This included structural and functional investigation of the potentially oncogenic splice variants of RASAL1, with a focus on exploring the molecular mechanisms and clinical impacts on thyroid cancer. RESULTS: We identified an aberrant alternative splice variant of RASAL1, known as RASAL1-004, that commonly compromised the function of RASAL1 in thyroid cancer. Specifically, we found common skipping of exon 18.1 in RASAL1, leading to the abundant formation of transcript RASAL1-004 in cancer, which was significantly associated with poor survival of patients with thyroid cancer. Mechanistically, Argonaute2 regulates exon 18.1 splicing by binding to the response element in exon 17 containing CCAGCC motif, promoting RASAL1-004 formation. The exon 18.1 skipping caused a conformational change in the RNA structure of RASAL1-004 at the junction of exons 17 and 18, resulting in ribosome stalling, halting RASAL1 translation. This reduced RAS GTPase-activating-like protein 1 (RASAL1 protein) synthesis, consequently leading to the functional loss of RASAL1. Compared with RASAL1-001, the canonical wild-type RASAL1 transcript, the absence of exon 18.1 in RASAL1-004 also conformationally altered the pleckstrin homology domain of RASAL1 protein, which, as we demonstrated, led to the loss of the ability of RASAL1 to localize with cell membrane, thereby impairing its RAS-inactivating function. We further demonstrated that compared with RASAL1-001, RASAL1-004 displayed impaired RAS-signaling pathway-suppressing and cancer cell-suppressing functions. CONCLUSIONS: This study identified a novel RASAL1-impairing mechanism, alternative to the classically known genetic and epigenetic mechanisms, for the inactivation of the tumor suppressor gene RASAL1 through aberrant AS to form RASAL1-004 with impaired protein translation. This represents a new oncogenic mechanism in thyroid cancer, with novel cancer biological, prognostic, and therapeutic-targeting implications in thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Liao J, Song J, Wang Z, et al. Functional Loss of the Tumor Suppressor Gene RASAL1 Through Formation of Aberrant Splice Variant RASAL1-004 as a Novel Oncogenic Mechanism in Thyroid Cancer. Thyroid. 2025. PMID: 41449763. doi:10.1177/10507256251401486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。